SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13D

INFORMATION TO BE INCLUDED IN STATEMENT FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a)

(Amendment No.     )*

THE FEMALE HEALTH COMPANY

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

314462102

(CUSIP Number)

Harry Fisch, M.D.

150 North Michigan Avenue

Suite 1580

Chicago, Illinois 60601

Telephone: 312-595-9123

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 31, 2016

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

Note. Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

13D

13D

13D

SCHEDULE 13D

This statement on Schedule 13D (this “Schedule 13D”) relates to the common stock, par value $0.01 per share (“FHC Common Stock”), of The Female Health Company (the “Issuer” or “FHC”), a Wisconsin corporation. The address of the Issuer’s principal executive office is 150 North Michigan Avenue, Suite 1580, Chicago, IL 60601.

(a) This Schedule 13D is being filed by Harry Fisch, M.D., an individual (“Fisch”), and K&H Fisch Family Partners, LLC, a limited liability company organized under the laws of New York (“Fisch Family Partners” and together with Fisch, the “Reporting Persons”). Fisch is the sole manager of Fisch Family Partners and has voting and investment control of the shares FHC Common Stock and Series 4 Preferred Stock held by Fisch Family Partners.

(d) and (e) To the knowledge of each Reporting Person, during the last five years, no Reporting Person has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or was a party to a civil proceeding of a judicial or administrative body resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violations with respect to such laws.

(f) Fisch is a citizen of the United States of America.

The Reporting Persons acquired shares of FHC Common Stock and Class A Preferred Stock – Series 4, par value $0.01 per share (“Series 4 Preferred Stock”), of the Issuer pursuant to the terms of that certain Amended and Restated Agreement and Plan of Merger, dated as of October 31, 2016 (the “Merger Agreement”), by and among the Issuer, Aspen Park Pharmaceuticals, Inc., a Delaware corporation (“APP”), and Blue Hen Acquisitions, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer (“APP Merger Sub”). Pursuant to the terms of the Merger Agreement, all outstanding shares of APP common stock and APP preferred stock were converted into the right to receive, in the aggregate, 2,000,000 shares of FHC Common Stock and 546,756 shares of Series 4 Preferred Stock.

Pursuant to the Amended Merger Agreement, (i) Fisch received 9,178 shares of FHC Common Stock and 2,509 shares of Series 4 Preferred Stock in exchange for 53,333 shares of APP common stock, (ii) Fisch and his spouse received 36,986 shares of FHC Common Stock and 10,111 shares of Series 4 Preferred Stock in exchange for 16,000 shares of APP preferred stock and (iii) Fisch Family Partners received 592,743 shares of FHC Common Stock and 162,043 shares of Series 4 Preferred Stock in exchange for 3,444,400 shares of APP common stock.

13D

The information contained in Items 3 and 6 of this statement is incorporated herein by reference.

On October 31, 2016, the Issuer, APP and APP Merger Sub entered into the Amended Merger Agreement, pursuant to which APP became a wholly-owned subsidiary of the Issuer through the merger of APP Merger Sub with and into APP with APP continuing as the surviving corporation (the “Merger”).

Pursuant to the terms of the Amended Merger Agreement and pursuant to the Merger, all outstanding shares of APP common stock and preferred stock were converted into the right to receive, in the aggregate, 2,000,000 shares of FHC Common Stock and 546,756 shares of Series 4 Preferred Stock. Each share of Series 4 Preferred Stock will automatically convert into 40 shares of FHC Common Stock upon the approval by the requisite vote of the Issuer’s stockholders of (i) an amendment to the Issuer’s Amended and Restated Articles of Incorporation to increase the total number of authorized shares of FHC Common Stock to a sufficient amount to permit such conversion and (ii) such conversion of the Series 4 Preferred Stock pursuant to the applicable NASDAQ rules. After giving effect to such conversion, the former APP stockholders will own approximately 23,870,000 shares of FHC Common Stock in total, constituting approximately 45% of the outstanding shares of FHC Common Stock as of the date of the Merger.

Amendment to Articles of Incorporation. On October 31, 2016, immediately prior to the closing of the Merger, the Issuer filed Articles of Amendment (the “Articles of Amendment”) to the Issuer’s Amended and Restated Articles of Incorporation containing the Statement of Terms of the Series 4 Preferred Stock. Pursuant to the Articles of Amendment, the terms of the Series 4 Preferred Stock include the following:

13D

Board Composition and Officer Appointments. Upon consummation of the Merger and pursuant to the terms of the Amended Merger Agreement (i) four members of the Board of Directors of the Issuer (the “Board”) resigned, the Board was set at nine directors and six new members of the Board were appointed, including Fisch, and (ii) Fisch was appointed as the Chief Corporate Officer of the Issuer. In addition, effective upon the consummation of the Merger, a new President and Chief Executive Officer and new Chief Financial Officer and Chief Operating Officer of the Issuer were appointed.

Stockholder Meeting. Pursuant to the terms of the Amended Merger Agreement, the Issuer has agreed, not later than the 2017 annual meeting of its stockholders, to submit to a duly held meeting of its stockholders for approval by the affirmative vote of the holders of Issuer’s capital stock required under the Wisconsin Business Corporation Law and NASDAQ Listing Rule 5635(a), the proposals required to be approved by the Issuer’s stockholders to effect the mandatory conversion of all of the shares of Series 4 Preferred Stock into shares of FHC Common Stock in accordance with the terms of the Articles of Amendment.

The foregoing summary is qualified in its entirety by reference to the Amended Merger Agreement and the Articles of Amendment, which are attached hereto as Exhibits 1 and 2, respectively, and incorporated herein by reference.

(a) and (b)        The Reporting Persons beneficially own FHC Common Stock as follows:

13D

The information contained in Item 4 of this statement is incorporated herein by reference.

The information contained in Items 3 and 4 of this statement is incorporated herein by reference.

Lock-Up Agreement. Each of Fisch, his spouse and Fisch Family Partners has entered into an Amended and Restated Lock-Up Agreement (the “Lock-Up Agreement”) with FHC which generally prohibits each such holder from transferring 75% of the shares of FHC Common Stock and Series 4 Preferred Stock which such holder received in the Merger for a period of 18 months following the closing of the Merger. The shares of FHC Common Stock and Series 4 Preferred Stock that are subject to the Lock-Up Agreement will be held in escrow for a period of one year after the closing of the Merger as the sole remedy for APP’s indemnification obligations set forth in the Amended Merger Agreement pursuant to the terms of an Escrow Agreement (the “Escrow Agreement”). Seventy-five percent of the shares held in escrow are eligible for release from escrow six months after the closing of the Merger, although any shares released from escrow will remain subject to the Lock-Up Agreement until the end of the lock-up term.

Registration Rights Agreement. In connection with the Amended Merger Agreement, the Issuer entered into a Registration Rights Agreement with the former stockholders of APP receiving shares of FHC Common Stock and Series 4 Preferred Stock in connection with the Merger, including Fisch, his spouse and Fisch Family Partners, pursuant to which such stockholders have been granted certain demand registration rights and piggyback registration rights to participate in subsequent registered offerings of FHC Common Stock, subject to the terms and conditions of the Lock-Up Agreement.

The foregoing summary is qualified in its entirety by reference to the Registration Rights Agreement, the form of the Lock-Up Agreement and the Escrow Agreement, which are attached as Exhibits 3, 4 and 5, respectively, and incorporated herein by reference.

13D

13D

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.